Abstract:AIM To evaluate the levels of metabolites and cytokines in the serum of patients with severe and non-severe idiosyncratic drug-induced liver injury (DILI) and to identify biomarkers of DILI severity. METHODS Gas chromatography-mass spectrometry (GC-MS) and ultraperformance liquid chromatography-mass spectrometry (UPLC-MS) based metabolomic approaches were used to evaluate the metabolome of serum samples from 29 DILI patients of severity grade 3 (non-severe), 27 of severity grade 4 (severe), and 36 healthy control (HC). The levels of total keratin-18 (K18), fragment K18, and 27 cytokines were determined by enzyme-linked immunosorbent assay. RESULTS The alkaline phosphatase activity ( p = 0.021) and international normalized ratio (INR) ( p < 0.001) differed significantly between the severe and non-severe groups. The severe group had a higher serum fragment K18 level than the non-severe group. A multivariate analysis showed good separation between all pairs of the HC, non-severe, and severe groups. According to the orthogonal partial least-squares-discriminant analysis (OPLS-DA) model, 14 metabolites were selected by GC-MS and 17 by UPLC-MS. Among these metabolites, the levels of 16 were increased and of 15 were decreased in the severe group. A pathway analysis revealed major changes in the primary bile acid biosynthesis and alpha-linolenic acid metabolic pathways. The levels of PDGF-bb, IP-10, IL-1Rα, MIP-1β, and TNF-α differed significantly between the severe and non-severe groups, and the levels of most of the metabolites were negatively correlated with those of these cytokines. An OPLS-DA model that included the detected metabolites and cytokines revealed clear separation of the severe and non-severe groups. CONCLUSION We identified 31 metabolites and 5 cytokines related to the severity of idiosyncratic DILI. The primary bile acid biosynthesis and alpha-linolenic acid metabolism pathways were also related to the severity of DILI. A model that incorporated the metabolites and cytokines showed clear separation between patients with severe and non-severe DILI, suggesting that these biomarkers have potential as indicators of DILI severity.

MicroRNAs in Drug-induced Liver Injury.

A Panel Of Serum Micrornas As Specific Biomarkers For Diagnosis Of Compound- And Herb-Induced Liver Injury In Rats

Novel Clinical Biomarkers for Drug-Induced Liver Injury.

Progress in the biomarker discovery for drug-induced liver injury]

Advances in drug-induced liver injury research: in vitro models, mechanisms, omics and gene modulation techniques

Alteration of Bile Acids and Omega-6 PUFAs Are Correlated With the Progression and Prognosis of Drug-Induced Liver Injury

The Immunological Mechanisms and Immune-Based Biomarkers of Drug-Induced Liver Injury

Identification of Drug-Induced Liver Injury Biomarkers from Multiple Microarrays Based on Machine Learning and Bioinformatics Analysis

Candidate biomarkers for the diagnosis and prognosis of drug‐induced liver injury: An international collaborative effort

Metabolite biomarkers of drug-induced liver injury

The Potential Role of Metabolomics in Drug-Induced Liver Injury (DILI) Assessment

Ultrasensitive Upconverting Nanoprobes for in Situ Imaging of Drug-Induced Liver Injury Using Mir-122 As the Biomarker

[Promoting Translational Research on Drug-Induced Liver Injury].

[Research Progress on Laboratory Diagnosis of Drug-Induced Liver Injury].

Metabolomics and Cytokine Analysis for Identification of Severe Drug-Induced Liver Injury.

A new prognostic model for drug-induced liver injury especially suitable for Chinese population

Sensitive detection of human drug-induced liver injury by measurement of microRNA-122 using single molecule arrays

Metabolomic approaches in the discovery of potential urinary biomarkers of drug-induced liver injury (DILI)

Insights gained into the injury mechanism of drug and herb induced liver injury in the hepatic microenvironment

Serum Metabolome and Targeted Bile Acid Profiling Reveals Potential Novel Biomarkers for Drug-Induced Liver Injury.

Amplification-free electrochemical biosensor detection of circulating microRNA to identify drug-induced liver injury